169 related articles for article (PubMed ID: 35288376)
1. Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases.
Arumahandi de Silva AN; Frommert LM; Albach FN; Klotsche J; Scholz V; Jeworowski LM; Schwarz T; Ten Hagen A; Zernicke J; Corman VM; Drosten C; Burmester GR; Biesen R
Ann Rheum Dis; 2022 Jun; 81(6):881-888. PubMed ID: 35288376
[TBL] [Abstract][Full Text] [Related]
2. Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease.
Frommert LM; Arumahandi de Silva AN; Zernicke J; Scholz V; Braun T; Jeworowski LM; Schwarz T; Tober-Lau P; Ten Hagen A; Habermann E; Kurth F; Sander LE; Corman VM; Burmester GR; Biesen R; Albach FN; Klotsche J
RMD Open; 2022 Dec; 8(2):. PubMed ID: 36597977
[TBL] [Abstract][Full Text] [Related]
3. Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination.
Habermann E; Gieselmann L; Tober-Lau P; Klotsche J; Albach FN; Ten Hagen A; Zernicke J; Ahmadov E; Arumahandi de Silva AN; Frommert LM; Kurth F; Sander LE; Burmester GR; Klein F; Biesen R
RMD Open; 2022 Oct; 8(2):. PubMed ID: 36216410
[TBL] [Abstract][Full Text] [Related]
4. A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases.
Tzioufas AG; Bakasis AD; Goules AV; Bitzogli K; Cinoku II; Chatzis LG; Argyropoulou OD; Venetsanopoulou AI; Mavrommati M; Stergiou IE; Pezoulas V; Voulgari PV; Katsimpari C; Katechis S; Gazi S; Katsifis G; Sfontouris CI; Georgountzos AI; Liossis SN; Papagoras C; Fotiadis DI; Skopouli FN; Vlachoyiannopoulos PG; Moutsopoulos HM
J Autoimmun; 2021 Dec; 125():102743. PubMed ID: 34757289
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive therapy and humoral response to third mRNA COVID-19 vaccination with a six-month interval in rheumatic disease patients.
Kashiwado Y; Kimoto Y; Ohshima S; Sawabe T; Irino K; Nakano S; Hiura J; Yonekawa A; Wang Q; Doi G; Ayano M; Mitoma H; Ono N; Arinobu Y; Niiro H; Hotta T; Kang D; Shimono N; Akashi K; Takeuchi T; Horiuchi T
Rheumatology (Oxford); 2024 Mar; 63(3):725-733. PubMed ID: 37289506
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate significantly reduces the humoral vaccination response against SARS-CoV-2 in older but not younger patients with rheumatoid arthritis.
Feuchtenberger M; Kovacs MS; Eder A; Nigg A; Schäfer A
Rheumatol Int; 2022 Jun; 42(6):959-966. PubMed ID: 35429290
[TBL] [Abstract][Full Text] [Related]
7. Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases.
Aikawa NE; Kupa LVK; Medeiros-Ribeiro AC; Saad CGS; Yuki EFN; Pasoto SG; Rojo PT; Pereira RMR; Shinjo SK; Sampaio-Barros PD; Andrade DCO; Halpern ASR; Fuller R; Souza FHC; Guedes LKN; Assad APL; Moraes JCB; Lopes MRU; Martins VAO; Betancourt L; Ribeiro CT; Sales LP; Bertoglio IM; Bonoldi VLN; Mello RLP; Balbi GGM; Sartori AMC; Antonangelo L; Silva CA; Bonfa E
Ann Rheum Dis; 2022 Jul; 81(7):1036-1043. PubMed ID: 35277389
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.
Furer V; Eviatar T; Zisman D; Peleg H; Paran D; Levartovsky D; Zisapel M; Elalouf O; Kaufman I; Meidan R; Broyde A; Polachek A; Wollman J; Litinsky I; Meridor K; Nochomovitz H; Silberman A; Rosenberg D; Feld J; Haddad A; Gazzit T; Elias M; Higazi N; Kharouf F; Shefer G; Sharon O; Pel S; Nevo S; Elkayam O
Ann Rheum Dis; 2021 Oct; 80(10):1330-1338. PubMed ID: 34127481
[TBL] [Abstract][Full Text] [Related]
9. Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination.
Andreica I; Blazquez-Navarro A; Sokolar J; Anft M; Kiltz U; Pfaender S; Vidal Blanco E; Westhoff T; Babel N; Stervbo U; Baraliakos X
RMD Open; 2022 Sep; 8(2):. PubMed ID: 36104115
[TBL] [Abstract][Full Text] [Related]
10. Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial.
Araujo CSR; Medeiros-Ribeiro AC; Saad CGS; Bonfiglioli KR; Domiciano DS; Shimabuco AY; Silva MSR; Yuki EFN; Pasoto SG; Pedrosa T; Kupa LVK; Zou G; Pereira RMR; Silva CA; Aikawa NE; Bonfa E
Ann Rheum Dis; 2022 Jun; 81(6):889-897. PubMed ID: 35193873
[TBL] [Abstract][Full Text] [Related]
11. The immunogenicity of seasonal and pandemic influenza vaccination in autoimmune inflammatory rheumatic patients-a 6-month follow-up prospective study.
Lakota K; Perdan-Pirkmajer K; Sodin-Šemrl S; Čučnik S; Šubelj V; Prosenc K; Mrak Poljšak K; Tomšič M; Ambrožič A; Praprotnik S
Clin Rheumatol; 2019 May; 38(5):1277-1292. PubMed ID: 30761436
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
[TBL] [Abstract][Full Text] [Related]
13. Robust neutralizing antibody response to SARS-CoV-2 mRNA vaccination in adolescents and young adults with childhood-onset rheumatic diseases.
Yeo JG; Chia WN; Teh KL; Book YX; Hoh SF; Gao X; Das L; Zhang J; Sutamam N; Lim AJM; Poh SL; Tay SH; Nay Yaung K; Ong XM; Hazirah SN; Chua CJH; Leong JY; Wang LF; Albani S; Arkachaisri T
Rheumatology (Oxford); 2022 Nov; 61(11):4472-4481. PubMed ID: 35199166
[TBL] [Abstract][Full Text] [Related]
14. Reduced humoral response to a third dose (booster) of SARS-CoV-2 mRNA vaccines by concomitant methotrexate therapy in elderly patients with rheumatoid arthritis.
Stahl D; Tho Pesch C; Brück C; Esser RL; Thiele J; Di Cristanziano V; Kofler DM
RMD Open; 2022 Oct; 8(2):. PubMed ID: 36216409
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity against the BNT162b2 mRNA COVID-19 Vaccine in Rheumatic Disease Patients Receiving Immunosuppressive Therapy.
Sugihara K; Wakiya R; Shimada H; Kameda T; Nakashima S; Kato M; Miyagi T; Mizusaki M; Mino R; Nomura Y; Inoo M; Kadowaki N; Dobashi H
Intern Med; 2022 Jul; 61(13):1953-1958. PubMed ID: 35466168
[TBL] [Abstract][Full Text] [Related]
16. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
17. The effects of methotrexate on the immune responses to the COVID-19 vaccines in the patients with immune-mediated inflammatory disease: A systematic review of clinical evidence.
Al-Haideri MT; Mannani R; Kaboli R; Gharebakhshi F; Darvishzadehdeldari S; Tahmasebi S; Faramarzi F; Cotrina-Aliaga JC; Khorasani S; Alimohammadi M; Darvishi M; Akhavan-Sigari R
Transpl Immunol; 2023 Aug; 79():101858. PubMed ID: 37236514
[TBL] [Abstract][Full Text] [Related]
18. Serological response to SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease treated with disease modifying anti-rheumatic drugs: A cohort study and a meta-analysis.
Auroux M; Laurent B; Coste B; Massy E; Mercier A; Durieu I; Confavreux CB; Lega JC; Mainbourg S; Coury F
Joint Bone Spine; 2022 Oct; 89(5):105380. PubMed ID: 35490940
[TBL] [Abstract][Full Text] [Related]
19. Improvement of humoral immunity by repeated dose-intensified COVID-19 vaccinations in primary non- to low-responders and B cell deficient rheumatic disease patients.
Ten Hagen A; Hermann S; Habermann E; Frommert LM; Arumahandi de Silva AN; Scholz V; Ghannam K; Klotsche J; Zernicke J; Alexander T; Burmester GR; Albach FN; Biesen R
J Autoimmun; 2023 Feb; 135():102996. PubMed ID: 36642057
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases.
Zheng YQ; Li HJ; Chen L; Lin SP
Sci Rep; 2022 Oct; 12(1):17955. PubMed ID: 36289319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
